Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 9/20 | 0.44 |
| ▸ | CA12 | O43570 | 8/20 | 0.44 |
| ▸ | EPM2A | O95278 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.38 |
| ▸ | WNT3A | P56704 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22531865 | 0.85 | CHRM2 (0.42) | CYP2A6CA2CA12PIK3CDKDM4E | |
| SCHEMBL4375362 | 0.82 | PKM (0.46) | CA2CA12DYRK1AKDM4E | |
| SCHEMBL9075377 | 0.81 | CA2 (0.51) | CYP2A6CA2CA12EPM2APTPRC | |
| SCHEMBL12135783 | 0.81 | CA2 (0.51) | CYP2A6CA2CA12EPM2APTPRC | |
| SCHEMBL17955745 | 0.81 | CYP2A6 (0.47) | CYP2A6CA2CA12EPM2APTPRC | |
| SCHEMBL3796719 | 0.81 | CYP2A6 (0.47) | CYP2A6CA2CA12EPM2APTPRC | |
| Hydrochloric Acid SCHEMBL27827959 | 0.79 | CYP2A6 (0.46) | CYP2A6CA2CA12EPM2APTPRC | |
| Hydrochloric Acid SCHEMBL27659768 | 0.79 | CYP2A6 (0.46) | CYP2A6CA2CA12EPM2APTPRC | |
| SCHEMBL23841198 | 0.77 | CA2 (0.45) | CYP2A6CA2CA12EPM2APTPRC | |
| SCHEMBL3793838 | 0.77 | CA2 (0.51) | CYP2A6CA2CA12EPM2APTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| EP-4719605-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GlaxoSmithKline Intellectual Property (No.4) Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4692094-A1 | SULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Beijing Konruns Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| CN-113226356-B | Activation of pyruvate kinase R | 诺沃挪第克健康护理股份公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2024246862-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| US-20240391922-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | Novo Nordisk Heathcare AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-12122778-B2 | Activating pyruvate kinase R | NOVO NORDISK HEALTH CARE AG (CH) | 2024-10-22 | — | — | US | disclosed |
| US-12071440-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | NOVO NORDISK HEALTH CARE AG (CH) | 2024-08-27 | — | — | US | disclosed |
| EP-3852791-B1 | ACTIVATING PYRUVATE KINASE R | NOVO NORDISK HEALTHCARE AG (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008022345-A2 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| CN-1997363-A | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2007-07-11 | — | — | CN | disclosed |
| EP-1750696-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2006-11-16 | — | — | US | disclosed |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005110428-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-1996028463-A1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | CYP2A6 32/4885CA2 1245/4885CA12 2922/4885 |
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | CYP2A6 1174/4885CA2 1341/4885CA12 4051/4885 |
| US-20240391922-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | PDK1, PKM, PKLR | CYP2A6 4614/4885CA2 3724/4885CA12 4874/4885 |
| US-12071440-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | PDK1, PKM, PKLR | CYP2A6 4614/4885CA2 3724/4885CA12 4874/4885 |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | CYP2A6 2831/4885CA2 4412/4885CA12 4388/4885 |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | CYP2A6 3106/4885CA2 3293/4885CA12 4266/4885 |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | CYP2A6 2831/4885CA2 4412/4885CA12 4388/4885 |
| US-12122778-B2 | Activating pyruvate kinase R | PDK1, PDK2, PKLR | CYP2A6 4550/4885CA2 4150/4885CA12 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.